Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, ...

On Monday, Raymond James reaffirmed its Market Perform rating on Amedisys stock, following the company’s fourth-quarter financial results for 2024. Amedisys reported a revenue of $598.1 million ...

Among the blue-chip-laden Dow Jones Industrial Average (DJINDICES: ^DJI), the two worst-performing stocks in the month of ...

Mutual of America Capital Management LLC decreased its position in shares of Amedisys, Inc. (NASDAQ:AMED – Free Report) by ...

On Monday, Raymond (NSE:RYMD) James reaffirmed its Market Perform rating on Amedisys stock, following the company’s fourth-quarter financial results for 2024. Amedisys reported a revenue of $598.1 ...

Shares of AMED stock opened at $92.03 on Tuesday. The business has a fifty day simple moving average of $91.69 and a 200 day simple moving average of $93.06. The company has a market cap of $3.01 ...

Amedisys, Inc. AMED reported fourth-quarter ... the contraction of both margins in the quarter does not bode well for the stock. On a positive note, the company’s top and bottom lines surged ...

Truist Financial analyst David S Macdonald maintained a Hold rating on Amedisys (AMED – Research Report) today and set a price target of ...

Amedisys (AMED) delivered earnings and revenue surprises of -8.57% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?